Sun Pharma Advanced Research Company Ltd.

BSE: SPARC532872ISIN INE232I01014

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹185.30+9.30 (+5.28%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹289.00
52W low: ₹108.20
Off 52W high: -35.88%
1M return: -2.83%
3M return: -15.08%
6M return: +17.99%
1Y return: +35.45%
20D avg volume: 70,964
50 DMA: ₹192.22
200 DMA: ₹178.30

Key ratios Consolidated

Market cap: ₹6,013 Cr
Current price: ₹185.30
52W high / low: ₹289.00 / ₹108.20
Face value: ₹1.00
P/E: 3.68
P/B: 4.17
EPS (TTM): ₹50.40
Book value / share: ₹44.44
ROE: —
ROCE: 112.00%
Operating margin: —
Net margin: —
Debt / equity: 0.42
Net debt: ₹554.98 Cr
Interest cover: 46.50
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: -17.3 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	30.03	39.92	1,853	8.45	7.86	9.64	27.19	14.91	12.86	16.81	16.56	13.86
	23.62	23.66	1.80	0.00	0.01	9.14	0.00	0.19	0.04	1.56	4.40	6.39
	53.65	63.58	1,855	8.45	7.87	18.78	27.19	15.10	12.90	18.37	20.96	20.25
	77.96	84.25	94.06	76.44	83.66	70.59	87.86	94.54	120.07	113.87	126.37	119.90
	9.95	7.66	5.16	7.21	6.10	5.13	5.70	4.58	8.31	4.53	7.46	9.03
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	29.33	29.61	26.02	31.18	29.51	31.32	29.85	30.99	38.48	54.26	50.03	29.98
	0.12	8.13	11.64	8.78	7.52	6.19	4.54	2.80	1.14	0.56	0.91	0.26
	2.20	2.20	2.40	2.57	2.56	2.68	2.95	3.14	3.16	3.14	3.07	3.16
	36.36	36.65	48.84	26.70	37.97	25.27	44.82	11.37	12.70	10.84	13.04	13.94
	-24.31	-20.67	1,761	-67.99	-75.79	-51.81	-60.67	-79.44	-107.17	-95.50	-105.41	-99.65
	0.00	0.00	0.00	-12.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	-24.31	-20.67	1,761	-80.35	-75.79	-51.81	-60.67	-79.44	-107.17	-95.50	-105.41	-99.65
	0.08	0.11	-0.38	0.07	0.06	0.06	0.90	0.07	0.16	0.40	0.38	0.00
	-24.39	-20.78	1,761	-80.42	-75.85	-51.87	-59.77	-79.51	-107.33	-95.90	-105.79	-99.65
	-0.75	-0.64	54.27	-2.48	-2.34	-1.60	-1.84	-2.45	-3.31	-2.96	-3.26	-3.07
Key metrics
	-21.99	-10.34	1,775	-69.00	-65.71	-42.94	-53.18	-73.50	-102.87	-91.80	-101.43	-96.23
	-73.20%	-25.90%	95.80%	-816.60%	-836.00%	-445.40%	-195.60%	-493.00%	-799.90%	-546.10%	-612.50%	-694.30%
	-81.20%	-52.10%	95.00%	-951.70%	-965.00%	-538.10%	-219.80%	-533.30%	-834.60%	-570.50%	-638.80%	-719.00%
	-1.60%	—	125.10%	—	40.30%	—	145.00%	—	—	—	—	—
	282.10%	314.10%	6,715.80%	-43.30%	-38.90%	-42.70%	64.20%	7.60%	—	—	—	—
	67.80%	59.90%	3,046.90%	-1.10%	29.30%	45.90%	43.50%	20.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,932	1,879	71.77	75.55
	49.08	10.95	1.79	29.47
	1,981	1,890	73.56	105.02
	332.71	324.75	416.34	491.85
	29.98	23.60	23.12	28.13
	0.00	0.00	0.00	—
	116.14	118.03	153.58	141.84
	28.67	34.13	9.04	1.69
	9.37	10.21	12.39	12.51
	148.55	138.78	218.21	53.87
	1,648	1,565	-342.78	-386.83
	-12.36	-12.36	0.00	0.00
	1,636	1,553	-342.78	-386.83
	-0.12	-0.19	-0.27	0.38
	1,636	1,553	-342.51	-387.21
	50.40	47.86	-10.55	-11.93
Key metrics
	1,674	1,597	-321.35	-372.63
	86.65%	85.00%	-447.70%	-493.20%
	84.68%	82.70%	-477.20%	-512.50%
	—	112.00%	862.20%	—
	3,140.97%	2,518.30%	-5.00%	—
	—	553.50%	11.50%	—
	—	-262.60	-370.63	—
	—	-0.15	1.05	—
	—	0.42	-1.19	—
	—	554.98	256.23	—
	—	-17.3	-497.7	—
Balance sheet
	—	2,171	335.53	—
	—	1,862	26.19	—
	—	1.16	1.96	—
	—	8.27	16.06	—
	—	0.00	0.00	—
	—	1,846	5.65	—
	—	85.18	98.70	—
	—	97.15	113.92	—
	—	754.09	374.24	—
	—	556.14	258.19	—
	—	556.14	158.19	—
	—	0.00	100.00	—
	—	1,339	-216.95	—
Cash flow
	—	-238.77	-360.29	—
	—	-23.50	157.66	—
	—	261.39	199.25	—
	—	23.83	10.34	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	30.03	39.92	1,853	8.45	7.86	9.64	27.19	14.91	12.86	16.81	16.56	13.86
	23.62	23.66	1.80	0.00	0.01	9.02	0.00	0.19	0.04	1.56	4.40	6.39
	53.65	63.58	1,855	8.45	7.87	18.66	27.19	15.10	12.90	18.37	20.96	20.25
	78.23	84.56	94.32	76.66	83.84	70.69	88.17	94.81	120.59	115.21	127.65	119.90
	9.95	7.66	5.16	7.21	6.10	5.13	5.70	4.58	8.31	4.53	7.46	9.03
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	23.89	24.16	21.08	26.90	26.19	27.68	24.83	26.41	28.78	28.94	26.72	29.98
	0.12	8.13	11.64	8.78	7.52	6.18	4.51	2.77	1.11	0.52	0.88	0.26
	2.20	2.20	2.40	2.56	2.57	2.54	2.55	2.75	2.77	2.76	2.69	3.16
	42.07	42.41	54.04	31.21	41.46	29.16	50.58	11.39	12.68	10.82	11.61	13.94
	-24.58	-20.98	1,761	-68.21	-75.97	-52.03	-60.98	-79.71	-107.69	-96.84	-106.69	-99.65
	0.00	0.00	0.00	-12.36	0.00	0.00	0.00	—	—	—	—	—
	-24.58	-20.98	1,761	-80.57	-75.97	-52.03	-60.98	-79.71	-107.69	-96.84	-106.69	-99.65
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	-24.58	-20.98	1,761	-80.57	-75.97	-52.03	-60.98	-79.71	-107.69	-96.84	-106.69	-99.65
	-0.76	-0.65	54.26	-2.48	-2.34	-1.60	-1.88	-2.46	-3.32	-2.98	-3.29	-3.07
Key metrics
	-22.26	-10.65	1,775	-69.23	-65.88	-43.31	-53.92	-74.19	-103.81	-93.56	-103.12	-96.23
	-74.10%	-26.70%	95.80%	-819.30%	-838.20%	-449.30%	-198.30%	-497.60%	-807.20%	-556.60%	-622.70%	-694.30%
	-81.90%	-52.60%	95.00%	-953.50%	-966.50%	-539.70%	-224.30%	-534.60%	-837.40%	-576.10%	-644.30%	-719.00%
	-1.60%	—	125.60%	—	39.40%	—	127.10%	—	—	—	—	—
	282.10%	314.10%	6,715.80%	-43.30%	-38.90%	-42.70%	64.20%	7.60%	—	—	—	—
	67.60%	59.70%	2,987.30%	-1.10%	29.50%	46.30%	42.80%	20.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,932	1,879	71.77	75.55	238.78	137.25
	49.08	10.83	1.79	29.47	10.88	6.84
	1,981	1,890	73.56	105.02	249.66	144.09
	333.77	325.51	418.78	493.13	472.24	347.49
	29.98	23.60	23.12	28.13	22.11	18.27
	0.00	0.00	0.00	—	—	—
	96.03	101.85	108.96	118.53	106.99	96.78
	28.67	34.12	8.91	1.66	7.63	13.33
	9.36	10.07	10.83	12.13	11.77	10.16
	169.73	155.87	266.96	52.44	42.32	29.66
	1,647	1,564	-345.22	-388.11	-222.58	-203.40
	-12.36	-12.36	0.00	—	—	—
	1,635	1,552	-345.22	-388.11	-222.58	-203.40
	0.00	0.00	0.00	—	—	—
	1,635	1,552	-345.22	-388.11	-222.58	-203.40
	50.37	47.83	-10.64	-11.96	-7.82	-7.73
Key metrics
	1,673	1,596	-325.48	-374.32	-203.18	-179.91
	86.59%	84.90%	-453.50%	-495.50%	-85.10%	-131.10%
	84.62%	82.60%	-481.00%	-513.70%	-93.20%	-148.20%
	—	112.40%	756.80%	—	—	—
	3,140.97%	2,518.30%	-5.00%	-68.40%	74.00%	—
	—	549.60%	11.10%	-74.40%	-9.40%	—
	—	-262.72	-372.75	—	—	—
	—	-0.15	1.05	—	—	—
	—	0.42	-1.17	—	—	—
	—	555.82	257.00	—	—	—
	—	-19.0	-550.9	—	—	—
Balance sheet
	—	2,168	329.29	—	—	—
	—	1,861	25.27	—	—	—
	—	0.32	1.19	—	—	—
	—	8.27	16.06	—	—	—
	—	0.00	0.00	—	—	—
	—	1,846	5.50	—	—	—
	—	85.18	95.27	—	—	—
	—	106.31	124.39	—	—	—
	—	756.82	373.73	—	—	—
	—	556.14	258.19	—	—	—
	—	556.14	158.19	—	—	—
	—	0.00	100.00	—	—	—
	—	1,334	-220.62	—	—	—
Cash flow
	—	-238.89	-362.41	—	—	—
	—	-23.51	157.66	—	—	—
	—	261.53	200.88	—	—	—
	—	23.83	10.34	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +98.91%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +3,140.97%
Profit YoY (TTM): +708.35%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +3,140.97%
Profit YoY (TTM): +712.64%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 65.69%

Quarter	September 2026	30 Jun 2026	June 2026
Promoter %	65.69%	65.69%	65.69%

Holder	Type	Holding	Previous	Change
Shanghvi Finance Private Limited	Promoter Group	42.28%	42.28%	0.00%
Dilip.S.Shanghvi	Promoter	19.05%	19.05%	0.00%
Sun Pharmaceutical Industries Key Employees Benefit Trust	Public	3.18%	3.18%	0.00%
Lakshdeep Investments & Finance (P) Ltd.	Public	1.86%	1.86%	0.00%
Aditya Medisales Limited	Promoter Group	1.51%	1.51%	0.00%
Raksha Sudhir Valia	Promoter Group	1.28%	1.28%	0.00%
Vijay Mohanlal Parekh	Public	1.13%	1.13%	0.00%
Paresh Mohanlal Parekh	Public	1.13%	1.13%	0.00%
Enam Holdings Pvt Ltd	Public	1.04%	—	—
Sudhir Vrundavandas Valia	Promoter Group	0.57%	0.57%	0.00%
Unimed Investments Limited	Promoter Group	0.39%	0.39%	0.00%
Vibha Dilip Shanghvi	Promoter Group	0.33%	0.33%	0.00%
Aalok Dilip Shanghvi	Promoter Group	0.11%	0.11%	0.00%
Vidhi Dilip Shanghvi	Promoter Group	0.11%	0.11%	0.00%
Shanghvi Family & Friends Benefit Trust	Promoter Group	0.05%	0.05%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Sun Pharma Advanced Research Company Ltd.	6,013	185.30	3.68	112.00%	+3,140.97% TTM	+712.64% TTM	+35.45%

Filings & corporate actions

Recent announcements

Newspaper Advertisement for Publication of Financial Results3 Nov 2026 · Company Update / Newspaper Publication
Monitoring Agency Report for the quarter ended September 30, 20262 Nov 2026 · Company Update / Monitoring Agency Report
Financial Results for the quarter and half year ended September 30, 20262 Nov 2026 · Result / Financial Results
Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited ....22 Oct 2026 · Board Meeting / Board Meeting
Confirmation Certificate under Regulation 74(5) of SEBI (DP) Regulations, 20187 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Update on Litigation under regulation 30 of SEBI (LODR), 20154 Oct 2026 · Company Update / General
Intimation regarding Closure of Trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Filing of Application for Reclassification with Stock Exchanges13 Aug 2026 · Company Update / General
Newspaper Advertisement for Publication of Financials11 Aug 2026 · Company Update / Newspaper Publication
Outcome of 21st Annual General Meeting of Sun Pharma Advanced Research Company Limited held on August 10, 202610 Aug 2026 · AGM/EGM / AGM
Monitoring Agency Report for the Quarter ended June 30, 202610 Aug 2026 · Company Update / Monitoring Agency Report
Financial Results10 Aug 2026 · Result / Financial Results
Outcome of the Board Meeting10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve unaudited ....3 Aug 2026 · Board Meeting / Board Meeting
Intimation for Receipt of Request for Reclassification of Shareholder Category27 Jul 2026 · Company Update / General
Newspaper Advertisement of 21st Annual General Meeting of Company and related information17 Jul 2026 · Company Update / Newspaper Publication
Business Responsibility and Sustainability Report for FY 2616 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of 21st Annual General Meeting along with the Annual Report for FY 2616 Jul 2026 · AGM/EGM / AGM
Annual Report 2025-26 and the Notice of 21st Annual General Meeting16 Jul 2026 · Others / Reg. 34 (1) Annual Report
Intimation for change in Director13 Jul 2026 · Company Update / Change in Directorate
Newspaper Advertisement- 21st Annual General Meeting of the Company9 Jul 2026 · Company Update / Newspaper Publication
21st Annual General Meeting of the Company6 Jul 2026 · AGM/EGM / AGM
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 20186 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation regarding Change in Senior Management Team of the Company26 Jun 2026 · Company Update / Change in Management
Termination of License Agreement with CMS Bridging DMCC25 Jun 2026 · Company Update / General
Intimation regarding Closure of Trading Window24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Statutory Auditors Certificate in terms of Regulation 169(5) of SEBI ICDRA Regualations, 201825 May 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd & PACs20 May 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Newspaper Advertisement for Publication of Financials20 May 2026 · Company Update / Newspaper Publication
Update on PDP-716 NDA19 May 2026 · Company Update / General
Allotment of 3,85,10,000 warrants pursuant to Preferential Issue19 May 2026 · Company Update / Allotment of Equity Shares
Audited Financial Results18 May 2026 · Result / Financial Results
Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve the Audited ....11 May 2026 · Board Meeting / Board Meeting
SPARC Annouces Sale of Priority Review Voucher for US $195 million30 Apr 2026 · Company Update / Press Release / Media Release
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 20186 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation Regarding Resignation of Dr. Shravanti Bhowmik as Head of Operations Management of the Company w.e.f. April 01, 20263 Apr 2026 · Company Update / Change in Management
Intimation Regarding Change in Senior Management Team of the Company27 Mar 2026 · Company Update / Change in Management
Response of Clarification sought from BSE Limited27 Mar 2026 · Company Update / General
The Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on March 27, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.27 Mar 2026 · Company Update / Clarification
Intimation regarding Closure of Trading Window26 Mar 2026 · Insider Trading / SAST / Closure of Trading Window

Board meetings

2 Nov 2026 Board Meeting - Financial Results
10 Aug 2026 Board Meeting - Financial Results